Overview

[Genetic Counselor]

Overview

[Genetic Counselor]

Spinal Muscular Atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by homozygous loss of the SMN1 gene (deletion or mutation of exon 7), which leads to insufficient survival motor neuron (SMN) protein and progressive degeneration of anterior horn motor neurons in the spinal cord. It is the leading inherited cause of infant death worldwide.

Disease severity is modified by a second, nearly identical gene called SMN2. SMN2 produces mostly a truncated, unstable protein, but a small fraction is full-length and functional — so the number of SMN2 copies a patient carries is inversely related to severity: more SMN2 copies generally means a milder, later-onset form. This is why SMN2 copy number is checked alongside the SMN1 result on every diagnostic report, and why it matters for treatment planning.

Clinical types, by age of onset and maximum motor milestone reached:
• Type 0 — prenatal/neonatal onset, most severe, rarely survives infancy without intervention.
• Type 1 (Werdnig-Hoffmann disease) — onset before 6 months, never sits independently; historically the most common form leading to death or permanent ventilation before age 2 without treatment.
• Type 2 — onset 6–18 months, can sit but never walks independently.
• Type 3 (Kugelberg-Welander disease) — onset after 18 months, achieves independent walking, may lose it over time.
• Type 4 — adult onset, mildest form.

Burden in India: an estimated 4,000 new SMA births occur in India each year, making it one of the most common severe genetic disorders in the country. Type 1 and Type 2 account for the majority of cases seen at Indian tertiary centers and are also the forms represented in the CTRI-registered trial.

Regulatory pathway for any SMA trial or therapy in India, under the New Drugs and Clinical Trials Rules, 2019:
1. CDSCO / DCGI — apex authority granting clinical trial permission and drug import/marketing approval via the online Sugam portal.
2. Review Committee on Genetic Manipulation (RCGM), under the Department of Biotechnology — reviews gene-therapy-specific preclinical safety, vector shedding, and construct design data (relevant here because AAV9-based OAV101/Zolgensma is a gene therapy product).
3. Subject Expert Committees (SEC) — evaluate clinical trial design, safety monitoring plans, and risk-benefit ratio before DCGI grants permission.
4. Institutional Ethics Committees (IEC) and Institutional Biosafety Committees (IBSC) — provide site-level oversight, informed consent review, and biosafety compliance.
5. CTRI (Clinical Trials Registry – India), hosted by ICMR’s National Institute of Medical Statistics — registration here is legally mandatory before any participant is enrolled. Always verify a trial’s CTRI number directly on ctri.nic.in before trusting it.

References:
• National Guidelines for Gene Therapy Product Development and Clinical Trials, ICMR — https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/guidelines_GTP.pdf
• CTRI — https://ctri.nic.in
• Spinal muscular atrophy: Molecular mechanism of pathogenesis, diagnosis, therapeutics, and clinical trials in the Indian context — Journal of Biosciences, https://link.springer.com/article/10.1007/s12038-023-00412-9
• India approves Zolgensma — https://theprint.in/health/india-approves-zolgensma-one-of-worlds-costliest-drugs-why-its-sparked-hope-but-also-concern/2730423/

[Author]

Posts